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Abstract P25, a calpain cleavage product of the cyclin-depen-
dent kinase 5 (Cdk5) activator p35, causes prolonged activation
of Cdk5. Although p25 has been shown to accumulate in brains
of patients with Alzheimer’s disease (AD), it is not known
whether p25 accumulation in AD is brain region-speci¢c. We
analyzed the amounts of p25 and p35 in human autopsy samples
from multiple brain regions including frontal cortex, inferior
parietal cortex and hippocampus using immunoblotting assays.
Our results show that the p25^p35 indices are higher in AD
than in the control groups in all three brain regions. The most
signi¢cant di¡erence in p25^p35 indices between AD and con-
trol groups is in the frontal cortex. No signi¢cant di¡erence in
calpain activity between AD and control groups is observed,
indicating that postmortem calpain activation cannot account
for the elevation of p25/p35 ratios in AD brains. Our results
support the notion that p25 accumulation deregulates Cdk5 ac-
tivity in AD brains, and the deregulated Cdk5 activity may
contribute to the pathogenesis of AD. . 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Alzheimer’s disease (AD) is the leading cause of senile de-
mentia. Recent evidence suggests that cyclin-dependent kinase
5 (Cdk5) plays a role in the pathogenesis of AD. The activity
of Cdk5 has been shown to be higher in the prefrontal cortex
of AD brains [1]. Immunohistochemical analyses indicate the
presence of Cdk5 in the early stage of neuro¢brillary tangles
[2], one of the two pathological hallmarks in AD. Neuro¢bril-
lary tangles are comprised primarily of hyperphosphorylated
microtubule-associated protein tau. Indeed, Cdk5 is one of the
major protein kinases that phosphorylate tau on multiple sites
[3].
Cdk5 is a ubiquitous serine/threonine protein kinase [4].
Enzymatic activity of Cdk5 requires association with one of
its regulatory activators, p35 or p39. P35 and p39 are 60%
identical in sequence. Both proteins are predominantly ex-
pressed in the nervous system [5,6]. P35 is subjected to two
alternative proteolytic pathways. First, p35 is normally de-
graded by the ubiquitin-dependent proteasome pathway.
This results in a short half-life of p35 which allows for strin-
gent regulation of Cdk5 catalytic activity [7]. Second, the cal-
cium-dependent cysteine protease calpain, which is activated
under neurotoxic conditions, cleaves p35 between Phe99 and
Ala100 to liberate a 25 kDa fragment termed ‘p25’ [8^10]. The
half-life of p25 is 5^10-fold longer than that of p35 [7]. Gen-
eration of p25, therefore, causes prolonged activation of Cdk5
[7]. Furthermore, the localization of p25 is di¡use in cells,
whereas p35 is mostly restricted to the cell membrane, as
judged by immunocytochemical analysis [8]. Several lines of
evidence suggest that p25 is neurotoxic. In primary cortical
neurons, overexpression of p25 results in apoptosis [7]. Trans-
genic mice expressing human p25 show cytoskeletal disrup-
tions and hyperphosphorylation of tau in certain areas of
the brain, providing evidence for a role of p25/Cdk5 in the
pathologic phosphorylation of tau [11]. In addition, applica-
tion of calpain or Cdk inhibitors markedly reduces p25 neuro-
toxicity induced by the L-amyloid peptides [8,12], suggesting
that p25 is a downstream e¡ector of the amyloid L peptides.
Interestingly, we found that the ratio of p25 to p35 is elevated
in postmortem brains of AD patients. This led us to propose
that increase in p25 level contributes to the pathogenesis of
AD [7].
Contrary to our ¢ndings, Yoo and Lubec reported that p25
was decreased in AD brain samples [13]. Taniguchi and col-
leagues also argued that p25 was not signi¢cantly increased in
AD brains [14]. To address the relationship of p25 and AD
more speci¢cally, we performed a large survey on the levels of
p25 and p35 in human brains. In addition, we also analyzed
p25 and p35 levels in three di¡erent brain regions including
the frontal cortex, inferior parietal cortex and hippocampus.
Postmortem intervals of all tissues analyzed were less than 7 h.
The activity of calpain in the postmortem brain samples was
also examined by detecting the breakdown products of cyto-
skeletal spectrin. Statistical analyses of these experiments sug-
gest that the p25/p35 ratio in AD brains is signi¢cantly higher
than that in age-matched control brains.
2. Materials and methods
2.1. Materials and bu¡ers
RIPA bu¡er contained 500 mM NaCl, 1% NP40, 0.5% deoxycholic
acid, 0.1% SDS, 2 mM EGTA, 2 mM EDTA and 50 mM Tris base,
pH 7.5. The 1% SDS bu¡er contained 1% SDS in RIPA bu¡er. All
solutions contained 1 mM dithiothreitol, 25 mM L-glycerolphosphate,
5 mM NaF, 0.5 mM Na3VO4, 0.1 mM phenylmethylsulfonyl £uoride,
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1 Wg/ml pepstatin A, 2 Wg/ml aprotinin, 1 Wg/ml leupeptin, and 2 WM
calpeptin. PBST solution was the phosphate-bu¡ered saline contain-
ing 0.2% Tween 20. Chemiluminescence reagents used in immunoblot-
ting assay were purchased from NEN Life Science Products (Boston,
MA, USA). Polyvinylidene di£uoride (PVDF) membrane (Immobi-
lon-P) was purchased from Millipore (Bedford, MA, USA). Chemi-
cals are reagent-grade. Polyclonal antibody p35 was raised against
full-length p35, recognizing p25 and p35. A monoclonal antibody
against non-erythroid spectrin was obtained from Chemicon (Teme-
cula, CA, USA). Film used in the chemiluminescent detection
was Kodak X-Omat Blue XB-1 (Eastman Kodak, New York, NY,
USA).
2.2. Preparation of brain tissue samples
Human brain samples from the frontal cortex and inferior parietal
cortex were provided by Dr. Yong Shen at the Sun Health Research
Institute (Sun City, AZ, USA). Samples from the superior frontal
gyrus, a region in the frontal cortex, and hippocampus were provided
by Dr. Barbara Sahagan at P¢zer (Groton, CT, USA). The superior
frontal gyrus samples were considered the frontal cortex in this report.
Samples were shipped on dry ice and immediately stored at 380‡C
upon arrival. Descriptions of the brain samples analyzed in this report
are listed in Table 1. The samples from the frontal cortex, superior
frontal gyrus, and inferior parietal cortex were homogenized in RIPA
bu¡er using a pre-chilled Dounce homogenizer. Hippocampal tissue
was prepared in a 1% SDS bu¡er. Cell lysates of each sample were
clari¢ed by centrifugation at 4000Ug at 4‡C for 30 min.
2.3. Immunoblotting assay, imaging and statistical analysis
A 100 Wg aliquot of proteins from each lysate was loaded and
resolved on 10% SDS^polyacrylamide gels using a standard Tris^gly-
cine SDS-PAGE protocol. Proteins were electrically transferred into
PVDF membranes. Immunoblotting was performed according to the
protocol provided by NEN Life Science Products. The polyclonal p35
antibody (2 Wg/ml) was prepared in PBST containing 5% non-fat dried
milk. The p35 antibody raised against p35 recognized both p35 and
p25, used to label p35 and p25. The spectrin antibody was used at a
concentration of 0.01 Wg/ml. Horseradish peroxidase (HRP)-conju-
gated anti-rabbit antibody (Amersham Biosciences, CA, USA) was
used at 1:5000 dilution in the p25 and p35 experiment and HRP-
conjugated anti-mouse antibody (Amersham Biosciences) was diluted
at 1:5000 in the spectrin experiment. The labeled proteins (p25, p35,
and spectrin) were visualized by chemiluminescent method and ¢lm
exposure. The images were digitalized and imported into a Windows
2000 computer using a calibrated ImageScanner scanner (Amersham
Biosciences). The digital images were obtained at a 16-bit gray mode
to provide 65 636 gray levels. The volumes of image spots were quan-
ti¢ed using the ImageMaster 3 software (Amersham Biosciences). The
unit of volumes given by the image measurement is an arbitrary unit.
The total units per spot were representations of the p25 or p35 levels
in the analyzed samples. The p25/p35 ratio was established and the
logarithm of each p25/p35 ratio was calculated and referred to as p25^
p35 index. Statistical calculations, including two-tailed Student’s
t-test, were performed using Microsoft Excel (Redmond, WA, USA).
3. Results and discussion
Tissues from a total of 28 AD brains and 25 age-matched
control brains were analyzed and shown in Table 1. All of the
brain samples came from di¡erent individuals. To minimize
the postmortem e¡ect of p25 production, we only analyzed
brain samples with postmortem intervals less than 7 h. The
average of the postmortem intervals in all sample groups was
approximately 2.5 h (Table 1).
The p35 antibody raised against full-length p35 recognizes
both p25 and p35 [7]. The levels of p25 and p35 in each
sample were determined by immunoblotting using the p35
antibody and analyzed using ImageMaster 3 software (see
Section 2). Using the p25/p35 value for comparison may
seem more straightforward but the conclusion reached is mis-
leading because a completely di¡erent result can be obtained
when the p35/p25 ratio is used instead of p25/p35. To elimi-
nate the discrepancy caused by using p25/p35 or p35/p25, we
used the logarithm of p25/p35, termed p25^p35 index, to
study p25 and p35. The use of logarithmic transformation
can resolve the non-additivity and heterogeneity of variance
[15] and has been applied in biological study [16]. A 99%
con¢dence limit was set. Samples located within the 99% con-
¢dence intervals were analyzed here. The logarithm of p25/p35
for each case (25 controls and 28 ADs) was plotted on a
scatter plot (Fig. 1A). The mean, S.D. and results from Stu-
dent’s t-test are listed in Table 2. In Fig. 1A, the p25^p35
indices in AD are, in general, higher than in the control.
The mean of the p25/p35 ratios in AD (0.705, shown in Table
2) is higher than that in the control (0.243, shown in Table 2).
In Student’s t-test, the P value is 0.0000359 when we compare
p25^p35 indices between the two groups (Table 2), suggesting
that the p25^p35 index in AD is signi¢cantly higher than that
in the control.
To study p25 and p35 more speci¢cally, we analyzed p25
and p35 levels by brain region, including frontal cortex, infe-
rior parietal cortex and hippocampus (Fig. 1B^D). The p25^
p35 indices in the AD groups tend to have higher values
compared to the corresponding controls. The means of p25^
p35 indices in the three AD groups are higher than those in
the corresponding controls. These results indicate that p25^
p35 indices in AD are elevated.
Statistical assays were further utilized to evaluate the p25^
p35 index in AD versus control brains, shown in Table 2. In
control groups, the means of p25^p35 indices in the frontal
Table 1
Basic information of analyzed brain samples
Brain region Gender (male/female) P.M.I.a (meanUS.D.) Age of death (meanUS.D.)
Frontal cortex
Control 8/2 3.06U 0.90 80.3U 10.3
AD 9/6 2.59U 0.86 83.6U 5.4
Inferior parietal cortex
Control 3/6 2.49U 0.74 80.0U 9.6
AD 7/0 3.32U 1.85 84.3U 5.1
Hippocampus
Control 4/2 2.93U 1.16 76.7U 14.4
AD 3/3 2.07U 0.51 83.7U 3.6
Total
Control 15/10 2.83U 0.92 79.2U 10.3
AD 19/9 2.66U 1.18 83.8U 5.0
aP.M.I.: postmortem interval.
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cortex, inferior parietal cortex, and hippocampus are 0.111,
0.194, and 0.537, respectively. These numbers showed that
p25^p35 indices were di¡erent in di¡erent brain regions. In
the AD groups, the mean p25^p35 indices in the three corre-
sponding regions are 0.541, 0.992, and 0.831 (Table 2). To
determine the change in p25/p35 ratios, we took the exponen-
tial of [log (p25/p35)AD3log (p25/p35)control]. The results
showed that the means of the p25/p35 ratios in the AD groups
were 2.0^6.3-fold higher than those in the control groups,
depending on the particular brain region analyzed. The high-
est p25/p35 case (p25/p35= 99.5, log (p25/35) = 2.00) appeared
in the AD inferior parietal cortex (Fig. 2C). The lowest p25/
p35 (p25/p35= 0.574, log (p25/p35) =30.241) was present in
the control inferior parietal cortex (Fig. 2C). Student’s t-tests
on the frontal cortex, inferior parietal cortex and hippocam-
pus demonstrate that the p25^p35 indices in the AD and
control are signi¢cantly di¡erent (P6 0.05) (Table 2). Based
on these results, we conclude that, in general, p25/p35 in the
AD brain is indeed increased. Owing to the paucity of the
tissue material that can be obtained and the limitation of
the semi-quantitative immunoblot assay method more detailed
studies in speci¢c sub-cortex regions could not be made. How-
ever, the p25^p35 index procedure described here appears to
be an acceptably reliable approach for comparative purposes.
We previously showed an increased conversion of p35 to
p25 in Brodmann’s areas 11 and 21 in AD brains which are
part of the frontal cortex [7]. We also showed that the p25/p35
ratios were as high as 20-fold in AD brains in the previous
report [7]. In this study, we report that the p25/p35 ratios in
AD are higher not only in frontal cortex but also in inferior
parietal cortex and hippocampus. The p25/p35 ratios in AD
can reach 10^100-fold. Our results are contradictory to the
Fig. 1. Comparison of p25^p35 indices of human control and AD brains. The result of log (p25/p35) for each brain sample is represented by a
circle. Bars represent the mean value of the group. A: Total brain samples. B: Frontal cortex. C: Inferior parietal cortex. D: Hippocampus.
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result reported by Yoo and Lubec where they ¢nd a decreased
p25 level in the frontal cortex of AD brains [13]. There are
several possible explanations for the discrepancy. One possi-
bility is the di¡erence in postmortem delays of samples. Sam-
ples with long postmortem delays (s 12 h) can have compli-
cated enzymatic activities, including protease activities. The
protease calpain that degrades p35 to generate p25 can be
activated during the postmortem period, thereby complicating
the analysis of the tissue samples. Another complication can
be caused by the variability within the control cases. In rodent
models, ischemia can trigger the generation of p25 [8]. More-
over, cycles of freeze^thawing also a¡ected the p25/p35 ratios,
as reported in a previous study [14]. Therefore, careful sample
handling is required in the analysis of p25 and p35.
Recent studies showed that the protease calpain was re-
sponsible for conversion of p35 to p25 [8^10]. Calpain has
been shown to be active during the postmortem period or in
hypoxia/ischemia conditions [17^19]. To determine if the in-
creased p25 in AD brains was generated during the postmor-
tem period, we examined postmortem calpain activity in the
AD and control frontal cortex samples by measuring the
cleavage of K-spectrin [18,19]. Large breakdown products of
spectrin are molecular markers used to represent postmortem
calpain activity [18]. Upon calpain cleavage, the full-length
spectrin (280 kDa) is broken down into 150 kDa and 140
kDa fragments, respectively [8,18]. Four samples for each
group (control and AD frontal cortices) were selected and
analyzed. The p25^p35 index in the selected AD samples
was signi¢cantly higher than that in the control (P6 0.05).
The breakdown levels of either p150 or p140 in the control
and AD groups are similar (Fig. 2). The result of a statistical
analysis on the breakdown levels of spectrin (Student’s t-test,
Ps 0.05) indicates that there is no signi¢cant di¡erence be-
tween the control and AD groups (Fig. 2). Taniguchi et al.
speculated that p25 in AD brains is perhaps generated post-
mortem [14]. However, in this report, the breakdown levels of
spectrin in the AD frontal cortex are similar to those in the
control groups, suggesting that AD brains do not harbor
higher postmortem calpain activity than control brains. This
is consistent with a previous biochemical analysis on calpain
activity in AD brains [20]. Thus, the observed increase in p25/
p35 ratio in AD can hardly be explained by de novo gener-
ation of p25 postmortem. Rather, the elevated p25/p35 ratio
in AD is presumably the result of accumulation of p25 in
particular a¥icted neurons over the course of the disease.
Real direct proof of p25 accumulation, based on de¢nite
chemical analysis, is not available.
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